FDA urges USPTO to tackle rising drug costs
14-09-2021
Abbott gets restraining order against ex-VP in COVID-19 trade secrets dispute
05-11-2020
Jarretera / Shutterstock.com
The US Food and Drug Administration (FDA) will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FDA, COVID-19, patent license, innovation, Advion, by Beijing Bohui Innovation Biotechnology Company, diagnostics, spectrometers, royalties
